Table 1.
Study cohort and demographic characteristics.
| Cohort Characteristic | Total, n = 103 |
|---|---|
| Age Median (IQR) | 55.0 (44.5, 63.0) |
| Gender n (%) | |
| Male | 25 (24.3%) |
| Female | 78 (75.7%) |
| Weight profile (in lbs) | |
| Weight at T0 (Start weight) | 199.2 (175.0, 235.0) |
| Weight at T1 | 195.5 (170.3, 226.9) |
| Weight at T2 | 181.8 (162.2, 215.8) |
| Change in weight (T1-T2) | 8.6 (2.0, 15.9) |
| Individuals with weight loss (at T2) | 82 (79.6%) |
| BMI kg/m2 (Median, IQR) | |
| BMI at T0 (Start BMI) | 32.3 (29.0, 37.4) |
| BMI at T1 | 31.8 (28.3, 36.6) |
| BMI at T2 | 29.7 (26.9, 34.8) |
| Change in BMI (T1-T2) | 1.4 (0.3, 2.7) |
| Consume alcohol at T0 n (%) | 66 (64.1%) |
| Weeks in program until T2 (Median, IQR) | 26 (21.0, 39.0) |
| Clinical characteristics | |
| Used recreational drugs at T0 n (%) | 15 (14.6%) |
| FGID at T0 n (%) | 61 (59.2%) |
| Other comorbidities at T0 n (%) | 88 (85.4%) |
| Use of antidepressants or anxiolytics at T0 n (%) | 36 (35%) |
Values are expressed as median (IQR) and percentages of available data. FGID, Functional Gastro-Intestinal Disorders; BMI, Body Mass Index; T0, at Baseline (during enrollment); T1, Early phase; T2, Follow-up phase.